MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.
Margherita TurinettoAndrea RicottiClaudia MarchettiCarmela PisanoClaudio ZamagniChiara CassaniPaola MalagutiAlessandra BaldoniPaolo ScolloGiuseppa ScandurraAlessandro ParisiGrazia ArtioliInnocenza PalaiaLaura VertechyAlice BergaminiElisa PicardoValentina TuninettiGiulia ScottoGiovanni ScambiaSandro PignataGiorgio ValabregaPublished in: Cancers (2023)
The MITO39 study showed a statistically significant difference in terms of PFS, suggesting that previous exposure to PARPi might inhibit the efficacy of PLD-Trabectedin. Regarding tolerability, no remarkable disparity was noted; PLD-Trabectedin was confirmed to be a well-tolerated scheme in both groups. To our knowledge, these are the first data regarding this topic, which we deem to be of great relevance in the current landscape.
Keyphrases
- open label
- double blind
- phase iii
- healthcare
- study protocol
- acute lymphoblastic leukemia
- clinical trial
- acute myeloid leukemia
- phase ii
- cross sectional
- dna damage
- placebo controlled
- drug delivery
- diffuse large b cell lymphoma
- electronic health record
- dna repair
- stem cells
- multiple myeloma
- big data
- cancer therapy
- randomized controlled trial
- single cell
- data analysis
- artificial intelligence
- cell therapy
- recombinant human